{
    "pmcid": "11285730",
    "qa_pairs": {
        "How were the nanobody libraries constructed for screening against the Omicron BA.1 spike protein?": [
            "From a llama immunized with the spike proteins of the Wuhan and Beta variants.",
            "From a camel immunized with the spike proteins of the Delta and Gamma variants.",
            "From a mouse immunized with the spike proteins of the Alpha and Delta variants.",
            "From a rabbit immunized with the spike proteins of the Omicron and Gamma variants."
        ],
        "What strategy does the study suggest for overcoming viral escape mutations in SARS-CoV-2 variants?": [
            "Targeting conserved epitopes on the RBD.",
            "Increasing the dosage of existing vaccines.",
            "Developing new antiviral drugs.",
            "Using monoclonal antibodies exclusively."
        ],
        "What was the outcome of administering trimeric nanobodies via the nasal route in a hamster model?": [
            "Effectively prevented weight loss and reduced viral loads.",
            "Caused significant weight gain and increased viral loads.",
            "Had no effect on weight or viral loads.",
            "Led to increased weight loss and unchanged viral loads."
        ],
        "What was the primary challenge posed by the Omicron variants of SARS-CoV-2 that necessitated the development of new biologics?": [
            "Their ability to evade immune responses.",
            "Their increased transmission rate.",
            "Their resistance to antiviral drugs.",
            "Their higher mutation rate compared to other variants."
        ],
        "Which nanobody was identified as binding directly at the ACE-2 interface of the Omicron RBD?": [
            "H6",
            "A8",
            "B5-5",
            "C3"
        ]
    }
}